晚期糖基化终产物受体（RAGE）作为肺部相关疾病治疗靶点的潜力。
The Potential of Receptor for Advanced Glycation End Products (RAGE) as a Therapeutic Target for Lung Associated Diseases.
机构信息
Department of Biotechnology, Daegu University, Gyeongsan, Gyeongbuk, Korea.
Department of Biotechnology, Maharishi Markandeshwar University, Mullana, Haryana, India.
出版信息
Curr Drug Targets. 2019;20(6):679-689. doi: 10.2174/1389450120666181120102159.
The receptor for advanced glycation end products (RAGE) is a multi-ligand pattern recognition receptor that is highly expressed in lung epithelial cells. It helps alveolar epithelial cells to maintain their morphology and specific architecture. However, in various pathophysiological conditions, pulmonary tissues express a supraphysiological level of RAGE and its ligands including advanced glycation end products, high mobility group box 1 proteins, and S100 proteins. On interaction with RAGE, these ligands stimulate downstream signaling that generates inflammation and oxidative stress leading to asthma, chronic obstructive pulmonary disease, lung cancers, idiopathic pulmonary fibrosis, acute lung injury, pneumonia, bronchopulmonary dysplasia, cystic fibrosis, and sepsis. Thus, pharmacological agents that can either suppress the production of RAGE or block its biological activity would offer promising therapeutic value against pathogenesis of the aforementioned lungassociated diseases. This review presents a comprehensive overview of the recent progress made in defining the functions of RAGE in lung-associated diseases.
晚期糖基化终产物受体（RAGE）是一种多配体模式识别受体，在肺上皮细胞中高度表达。它有助于肺泡上皮细胞维持其形态和特定结构。然而，在各种病理生理条件下，肺组织表达超生理水平的 RAGE 及其配体，包括晚期糖基化终产物、高迁移率族蛋白 B1 蛋白和 S100 蛋白。与 RAGE 相互作用时，这些配体刺激下游信号转导，产生炎症和氧化应激，导致哮喘、慢性阻塞性肺疾病、肺癌、特发性肺纤维化、急性肺损伤、肺炎、支气管肺发育不良、囊性纤维化和脓毒症。因此，能够抑制 RAGE 产生或阻断其生物学活性的药理学制剂将为治疗上述与肺相关疾病的发病机制提供有希望的治疗价值。本文综述了近年来在定义 RAGE 在与肺相关疾病中的作用方面所取得的进展。
Zotero 插件